Zydus completes Phase-I trials of its single dose

Zydus completes Phase-I trials of its single dose

by admin- Thursday, February 4th, 2021 04:07:52 PM

Zydus Cadila has introduced that its antimalarial compound ZY19489 (MMV253) in improvement with Swiss-primarily based product development partnership Medicines for Malaria Venture (MMV) has now completed Phase I medical evaluation. In the first in people examine performed in Australia, escalating doses of 25 to 1500 mg have been administered to healthy human volunteers. Emerging pharmacokinetic (PK) and safety statistics were evaluated with the aid of a safety statistics overview committee.

News Updates